Search
EHA-SWG Scientific Meeting on Aging and Hematology
Dates: October 12-14, 2018
Location: Warsaw, Poland
Chair: D Bron
Organized by:
EHA & the EHA Scientific Working Group on Aging and Hematology
Organizing committee:
D Bron, Institut Jules Bordet, Brussels, Belgium
L Adès, Hopital Saint Louis, Paris, France
R Cordoba, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
T Fulöp, Université…
EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology"
EHA & the EHA Scientific Working Group on Hematology and Aging are happy to announce their recent collaboration in organizing a virtual meeting program providing delegates with the latest insights in the field of geriatric hematology, presented by leading hematologists.
Read moreAging and Hematology
The SWG "Aging and Hematology" has four main goals for the next four years (2019-2023):
To share clinically useful tools in assessing frailty and comorbidities in older adults with hematologic malignancies.
Effective treatment of aging patients with hematological diseases discussed during SWG Aging meeting in Poland
The progress in the field of aging and the optimal and rational approaches of "fit" and "unfit" older patients with malignant hemopathies was the focus of the three-day EHA-SWG Scientific Meeting on Aging and Hematology held on October 12-14, 2018 in…
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreAppointment of new EHA Managing Director
The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreHelping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read moreEHA-SWG Scientific Meeting on Patient-centered Geriatric Hematology - report
Live sessions: October 6-7, 2021
Chairs: Prof R Cordoba (Spain) and Dr V Goede (Germany)
An international group of hematologists, specialist nurses, patient advocates, geriatricians, basic research, and pharma representatives gathered digitally to participate in this meeting.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- »